SecBot SecBot
SECBOTREPLAY Home › Report › PHAR

PHAR · Pharming Group received a positive opinion from the European Medicines…

Pharming Group N.V. · 6-K filed Mar 27, 2026 at 07:35 ET

At the news

BULLISHIMPACT 8/10

6-K filed Mar 27, 2026 at 07:35 ET

Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3K) syndrome (APDS) in adult and pediatric patients 12 years and older. If approved by the European Commission, Joenja would become the first approved treatment for APDS in the European Union.

  • CHMP adopted a positive opinion recommending marketing authorization for Joenja (leniolisib) for APDS treatment
  • Final European Commission decision expected in Q2 2026
  • If approved, Joenja would be the first treatment for APDS in the EU
  • Approval would be valid in all 27 EU member states plus Norway, Iceland, and Liechtenstein

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access